Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT06410534
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CARE1 Pragmatic Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT06364917
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 25
- Registration Number
- NCT06365619
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- 7 Hills Pharma, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT06362369
- Locations
- 🇺🇸
Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸Dartmouth Hitchcock, Lebanon, New Hampshire, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 250
- Registration Number
- NCT06361563
- Locations
- 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 700
- Registration Number
- NCT06361576
- Locations
- 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada
ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT06357858
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 124
- Registration Number
- NCT06346197
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT06325683
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.